How We Can Change the World

Too many people suffer from a wide array of health issues today.

  • Kidney failure
  • Diabetes
  • Parkinson’s
  • Muscle injury
  • Peripheral nerve injury
  • Stress urinary incontinence
  • Pelvic organ prolapse
  • Fecal incontinence

We aim to change this. Our technology is an opportunity to cure major diseases without drugs, surgery and intrusive implants. We’ve created a breakthrough using non-invasive stem cell therapy, which applies special acoustic waves to help the body replace old cell and repair bodily damage.

Not only does this improve the quality of people’s lives, it help reduce the $1 trillion in health care costs in the developed world and can provide advanced care at low cost to poor countries.

Envision living life to the fullest!

Tom F. Lue, MD, ScD (Hon), FACS – Co-founder;Principal Scientific Advisor.

Dr. Lue is Professor and Emil Tanagho Endowed Chair in Clinical Urology at the University of California San Francisco and medical director of the Knuppe Molecular Urology Laboratory. Dr. Lue is an internationally recognized expert on treatment of male sexual dysfunction and a pioneer in surgical methods to treat refractory ED. His research team proved that PDE5 inhibitors enhance erection in animals, providing the scientific basis for Viagra, Levitra and Cialis. He is also an expert on incontinence and developed the first animal model of female stress urinary incontinence,now used widely to study potential treatments. He is co-inventor of the sacral stimulation method of treating urge incontinence, the technology underlying Medtronic’s Interstim product line. Dr. Lue graduated with highest honors from the Kaohsiung Medical University in Taiwan and completed his urologic training at the State University of New York Downstate Medical Center. He has authored or co-authored twelve books and more than 380 publications. He is the recipient of numerous honors, including the Gold Cystoscope Award from the American Urological Association and an award for most innovative research from the American Foundation of Urologic Disease